{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:18:24Z","timestamp":1785860304601,"version":"3.56.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuropathic pain remains a significant clinical problem that necessitates the development of more effective treatment options. Compared with commonly used clinical drugs, such as gabapentin and pregabalin, mirogabalin is a novel gabapentinoid that exhibits greater affinity and selectivity for the \u03b12\u03b4-1\/-2 subunits of voltage-gated calcium channels, properties associated with strong nociceptive modulation. The aim of this study was to determine whether and how mirogabalin influences neuropathy symptoms and the antinociceptive effects of antidepressants (amitriptyline and duloxetine).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Studies were conducted in mice after chronic constriction injury of the sciatic nerve. On Day 7, a single intraperitoneal administration of mirogabalin (5\u201360\u2009mg\/kg), amitriptyline (1\u201310\u2009mg\/kg), or duloxetine (10\u201330\u2009mg\/kg) at various doses was performed. Additionally, mirogabalin (10\u2009mg\/kg) was chronically injected twice daily, while amitriptyline (5\u2009mg\/kg) or duloxetine (10\u2009mg\/kg) was administered once daily. Hypersensitivity was assessed using the von Frey and the cold plate tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using a mouse model of neuropathy, a single injection of mirogabalin, amitriptyline, or duloxetine reduced tactile and thermal hypersensitivity to a similar degree, with the most durable effect observed with mirogabalin, persisting up to 6\u2009hours. Repeated twice-daily intraperitoneal administration of mirogabalin combined with once-daily intraperitoneal dosing of amitriptyline or duloxetine resulted in a potentiated anti-nociceptive response in the used model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results may serve as a basis for further evaluation of the potential use of mirogabalin in the clinical treatment of neuropathic pain. Furthermore, they suggest that using mirogabalin together with amitriptyline or duloxetine may provide significant therapeutic benefits, enabling the use of lower doses of these medications, which may reduce the risk of adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-026-00862-6","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:16:22Z","timestamp":1779941782000},"page":"1058-1073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic potential of combining mirogabalin with antidepressants in relieving hypersensitivity: evidence from a mouse model of neuropathic pain"],"prefix":"10.1007","volume":"78","author":[{"given":"Renata","family":"Zaj\u0105czkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Ciechanowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Ciapa\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioletta","family":"Makuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Wordliczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kocot-K\u0119pska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Mika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"10","key":"862_CR1","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/J.PAIN.2011.06.017","volume":"152","author":"TS Jensen","year":"2011","unstructured":"Jensen TS, Baron R, Haanp\u00e4\u00e4 M, Kalso E, Loeser JD, Rice ASCTreede R-D, et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204\u201305. https:\/\/doi.org\/10.1016\/J.PAIN.2011.06.017.","journal-title":"Pain"},{"issue":"12","key":"862_CR2","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/J.PAIN.2011.09.014","volume":"152","author":"N Attal","year":"2011","unstructured":"Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011;152(12):2836\u201343. https:\/\/doi.org\/10.1016\/J.PAIN.2011.09.014.","journal-title":"Pain"},{"issue":"6","key":"862_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/MEDICINA61061063","volume":"61","author":"AD Kaye","year":"2025","unstructured":"Kaye AD, Armistead G, Amedio LS, Manthei ME, Ahmadzadeh SBernhardt B, Shekoohi S, et al. Evolving treatment strategies for neuropathic pain: a narrative review. Medicina (Kaunas). 2025;61(6):61. https:\/\/doi.org\/10.3390\/MEDICINA61061063.","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"862_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","volume":"155","author":"O van Hecke","year":"2014","unstructured":"van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654\u201362. https:\/\/doi.org\/10.1016\/j.pain.2013.11.013.","journal-title":"Pain"},{"issue":"1","key":"862_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/J.BJA.2023.04.021","volume":"131","author":"N Attal","year":"2023","unstructured":"Attal N, Bouhassira D, Colvin L. Advances and challenges in neuropathic pain: a narrative review and future directions. Br J Anaesth. 2023;131(1):79\u201392. https:\/\/doi.org\/10.1016\/J.BJA.2023.04.021.","journal-title":"Br J Anaesth"},{"issue":"5","key":"862_CR6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/MUS.28286","volume":"71","author":"ER Zeldin","year":"2025","unstructured":"Zeldin ER, Goddard AR, Boyle MS, Madathil RL, Rosenvall E, Majithia KA, et al. An overview of the non-procedural treatment options for peripheral neuropathic pain. Muscle Nerve. 2025;71(5):791\u2013801. https:\/\/doi.org\/10.1002\/MUS.28286.","journal-title":"Muscle Nerve"},{"issue":"2","key":"862_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162. https:\/\/doi.org\/10.1016\/S1474-4422(14)70251-0.","journal-title":"The Lancet Neurol"},{"issue":"4","key":"862_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/S40265-019-01070-8","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks ED. Mirogabalin: first global approval. Drugs. 2019;79(4):463\u201368. https:\/\/doi.org\/10.1007\/S40265-019-01070-8.","journal-title":"Drugs"},{"issue":"1","key":"862_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/S40122-021-00255-Y","volume":"10","author":"Y Kimura","year":"2021","unstructured":"Kimura Y, Yamaguchi S, Suzuki T, Kato J, Chiba S, Hirakawa N, et al. Switching from pregabalin to mirogabalin in patients with peripheral neuropathic pain: a multi-center, prospective, single-arm, open-label study (MIROP study). Pain Ther. 2021;10(1):711\u201327. https:\/\/doi.org\/10.1007\/S40122-021-00255-Y.","journal-title":"Pain Ther"},{"key":"862_CR10","doi-asserted-by":"publisher","unstructured":"Ushida T, Katayama Y, Hiasa Y, Nishihara M, Tajima F, Katoh S, et al. Mirogabalin for central neuropathic pain after spinal cord injury: a Randomized, Double-blind, placebo-Controlled, phase 3 study in Asia. Neurology. 2023;100(11). https:\/\/doi.org\/10.1212\/WNL.0000000000201709.","DOI":"10.1212\/WNL.0000000000201709"},{"key":"862_CR11","doi-asserted-by":"publisher","first-page":"1398442","DOI":"10.3389\/fpain.2024.1398442","volume":"5","author":"S Ayub","year":"2024","unstructured":"Ayub S, Bachu AK, Jain L, Parnia S, Bhivandkar S, Ahmed R, et al. Non-opioid psychiatric medications for chronic pain: systematic review and meta-analysis. Front Pain Res. 2024;5:1398442. https:\/\/doi.org\/10.3389\/fpain.2024.1398442.","journal-title":"Front. Pain Res"},{"key":"862_CR12","doi-asserted-by":"publisher","unstructured":"Yang F, Wang Y, Zhang M, Yu S. Mirogabalin as a novel calcium channel \u03b12\u03b4 ligand for the treatment of neuropathic pain: a review of clinical update. Front Pharmacol. 2024, 15;15. https:\/\/doi.org\/10.3389\/FPHAR.2024.1491570.","DOI":"10.3389\/FPHAR.2024.1491570"},{"issue":"6","key":"862_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/CPDD.448","volume":"7","author":"M Jansen","year":"2018","unstructured":"Jansen M, Warrington S, Dishy V, Ohwada S, Johnson L, Brown K, et al. A Randomized, placebo-Controlled, Double-blind study of the safety, Tolerability, pharmacokinetics, and pharmacodynamics of single and repeated doses of mirogabalin in healthy Asian volunteers. Clin Pharm Drug Dev. 2018;7(6):661\u201369. https:\/\/doi.org\/10.1002\/CPDD.448.","journal-title":"Clin Pharm Drug Dev"},{"issue":"3","key":"862_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Y Domon","year":"2018","unstructured":"Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, et al. Binding characteristics and Analgesic effects of mirogabalin, a novel ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 2018;365(3):573\u201382. https:\/\/doi.org\/10.1124\/jpet.117.247551.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"862_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.31083\/ph.2018.8550","volume":"73","author":"Y Domon","year":"2018","unstructured":"Domon Y, Kitano Y, Makino M. Analgesic effects of the novel \u03b12\u03b4 ligand mirogabalin in a rat model of spinal cord injury. Pharmazie. 2018;73(11):659\u201361. https:\/\/doi.org\/10.31083\/ph.2018.8550.","journal-title":"Pharmazie"},{"issue":"10353","key":"862_CR16","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0140-6736(22)01472-6","volume":"400","author":"S Tesfaye","year":"2022","unstructured":"Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Julious S, et al. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet (Lond, Engl). 2022;400(10353):680\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(22)01472-6.","journal-title":"Lancet (Lond, Engl)"},{"issue":"5\u20136","key":"862_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/17581869.2024.2370758","volume":"14","author":"AK Saxena","year":"2024","unstructured":"Saxena AK, Thanikkal N, Chilkoti GT, Gondode PG, Sharma T, Banerjee BD. PPAR\u03b3 and AKt gene modulation following pregabalin and duloxetine combination for painful diabetic polyneuropathy. Pain Manag. 2024;14(5\u20136):273\u201381. https:\/\/doi.org\/10.1080\/17581869.2024.2370758.","journal-title":"Pain Manag"},{"key":"862_CR18","doi-asserted-by":"publisher","unstructured":"Rodrigues RF, Kawano T, Placido R V, Costa LH, Podesta MHMC, Santos RS, et al. Investigation of the combination of pregabalin with duloxetine or amitriptyline on the pharmacokinetics and antiallodynic effect during neuropathic pain in rats. Pain Physician. 2021;24:E511\u201320. https:\/\/doi.org\/10.36076\/ppj.2021.24.E511.","DOI":"10.36076\/ppj.2021.24.E511"},{"issue":"5","key":"862_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/J.NEUROL.2020.01.361","volume":"176","author":"X Moisset","year":"2020","unstructured":"Moisset X, Bouhassira D, Avez Couturier J, Alchaar H, Conradi S, Delmotte MH, et al. Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations. Revue Neurologique. 2020;176(5):325\u201352. https:\/\/doi.org\/10.1016\/J.NEUROL.2020.01.361.","journal-title":"Revue Neurologique"},{"issue":"1","key":"862_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/ph15010088","volume":"15","author":"R Zaj\u0105czkowska","year":"2022","unstructured":"Zaj\u0105czkowska R, Rojewska E, Ciechanowska A, Pawlik K, Ciapa\u0142a K, Kocot-K\u0119pska M, et al. Mirogabalin Decreases pain-like behaviours and improves opioid and ketamine antinociception in a mouse model of neuropathic pain. Pharmaceuticals. 2022;15(1):88. https:\/\/doi.org\/10.3390\/ph15010088.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"862_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/S40780-025-00464-Z","volume":"11","author":"H Iwasaki","year":"2025","unstructured":"Iwasaki H, Kato H, Koseki T, Kondo M, Yamada S. Incidence of somnolence and dizziness induced by mirogabalin and pregabalin under opioid treatment: a single-center observational study. J Pharm Health Care Sci. 2025;11(1):11. https:\/\/doi.org\/10.1186\/S40780-025-00464-Z.","journal-title":"J Pharm Health Care Sci"},{"issue":"1","key":"862_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","volume":"33","author":"GJ Bennett","year":"1988","unstructured":"Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33(1):87\u2013107. https:\/\/doi.org\/10.1016\/0304-3959(88)90209-6.","journal-title":"Pain"},{"issue":"2\u20133","key":"862_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejphar.2007.01.013","volume":"560","author":"J Mika","year":"2007","unstructured":"Mika J, Osikowicz M, Makuch W, Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol. 2007;560(2\u20133):142\u201349. https:\/\/doi.org\/10.1016\/j.ejphar.2007.01.013.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"862_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2307\/2348009","volume":"31","author":"ID Hill","year":"1982","unstructured":"Hill ID, Tallarida RJ, Murray RB. Manual of pharmacologic calculations with computer programs. Appl Stat. 1982;31(3):307. https:\/\/doi.org\/10.2307\/2348009.","journal-title":"Appl Stat"},{"issue":"46","key":"862_CR25","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/PNAS.0409066103","volume":"103","author":"MJ Field","year":"2006","unstructured":"Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, et al. Identification of the \u03b1 2 -\u03b4-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA. 2006;103(46):17537\u201342. https:\/\/doi.org\/10.1073\/PNAS.0409066103.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"862_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0002-9440(10)63362-7","volume":"165","author":"V Ivanov S","year":"2004","unstructured":"Ivanov S V, Ward JM, Tessarollo L, McAreavey D, Sachdev V, Fananapazir L, et al. Cerebellar ataxia, seizures, premature death, and cardiac abnormalities in mice with targeted disruption of the Cacna2d2 gene. Am J Pathol. 2004;165(3):1007\u201318. https:\/\/doi.org\/10.1016\/S0002-9440(10)63362-7.","journal-title":"Am J Pathol"},{"issue":"6","key":"862_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5812\/AAPM.121402","volume":"11","author":"EY Chen","year":"2021","unstructured":"Chen EY, Beutler SS, Kaye AD, Edinoff AN, Khademi SH, Stoltz AE, et al. Mirogabalin as a novel gabapentinoid for the treatment of chronic pain conditions: an analysis of current evidence. Anesth Pain Med. 2021;11(6):11. https:\/\/doi.org\/10.5812\/AAPM.121402.","journal-title":"Anesth Pain Med"},{"issue":"3","key":"862_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.31083\/2019.8833","volume":"74","author":"Y Kitano","year":"2019","unstructured":"Kitano Y, Wakimoto S, Tamura S, Kubota K, Domon Y, Arakawa N, et al. Effects of mirogabalin, a novel ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels, on N-type calcium channel currents of rat dorsal root ganglion culture neurons. Pharmazie. 2019;74(3):147\u201349. https:\/\/doi.org\/10.31083\/2019.8833.","journal-title":"Pharmazie"},{"issue":"7","key":"862_CR29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3390\/ph16071023","volume":"16","author":"R Zaj\u0105czkowska","year":"2023","unstructured":"Zaj\u0105czkowska R, Pawlik K, Ciapa\u0142a K, Piotrowska A, Ciechanowska A, Rojewska E, et al. Mirogabalin decreases pain-like behaviors by inhibiting the Microglial\/Macrophage activation, p38MAPK signaling, and pronociceptive CCL2 and CCL5 release in a mouse model of neuropathic pain. Pharmaceuticals. 2023;16(7):1023. https:\/\/doi.org\/10.3390\/ph16071023.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"862_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000495425","volume":"26","author":"P Hundehege","year":"2018","unstructured":"Hundehege P, Fernandez-Orth J, R\u00f6mer P, Ruck T, M\u00fcntefering T, Eichler S, et al. Targeting voltage-dependent calcium channels with pregabalin exerts a direct neuroprotective effect in an animal model of multiple sclerosis. Neurosignals. 2018;26(1):77\u201393. https:\/\/doi.org\/10.1159\/000495425.","journal-title":"Neurosignals"},{"issue":"6","key":"862_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41582-024-00966-8","volume":"20","author":"CM Kaplan","year":"2024","unstructured":"Kaplan CM, Kelleher E, Irani A, Schrepf A, Clauw DJ, Harte SE. Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms. Nat Rev Neurol. 2024;20(6):347\u201363. https:\/\/doi.org\/10.1038\/s41582-024-00966-8.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"862_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/J.JPHS.2025.03.004","volume":"158","author":"M Yajima","year":"2025","unstructured":"Yajima M, Takahashi Y, Uezono Y, Kato F. Mirogabalin and pregabalin alleviate nociplastic sensitization induced by chemogenetic activation of the central amygdala neurons in rodents. J Pharmacological Sci. 2025;158(2):77\u201383. https:\/\/doi.org\/10.1016\/J.JPHS.2025.03.004.","journal-title":"J Pharmacological Sci"},{"issue":"13","key":"862_CR33","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.3390\/ijms20133130","volume":"20","author":"S Yang","year":"2019","unstructured":"Yang S, Chang MC. Chronic pain: structural and functional changes in brain structures and associated negative affective states. IJMS. 2019, 20;20(13):3130. https:\/\/doi.org\/10.3390\/ijms20133130.","journal-title":"IJMS"},{"issue":"10","key":"862_CR34","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1523\/JNEUROSCI.23-10-04017.2003","volume":"23","author":"SX Jin","year":"2003","unstructured":"Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci. 2003;23(10):4017\u201322. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-10-04017.2003.","journal-title":"J Neurosci"},{"key":"862_CR35","doi-asserted-by":"publisher","unstructured":"Rojewska E, Popiolek-Barczyk K, Kolosowska N, Piotrowska A, Zychowska M, Makuch W, et al. PD98059 influences immune factors and enhances opioid analgesia in model of neuropathy. PLoS One. 2015;10(10):e0138583. https:\/\/doi.org\/10.1371\/journal.pone.0138583.","DOI":"10.1371\/journal.pone.0138583"},{"issue":"5","key":"862_CR36","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1213\/ANE.0000000000000174","volume":"118","author":"C Zhou","year":"2014","unstructured":"Zhou C, Shi X, Huang H, Zhu Y, Wu Y. Montelukast attenuates neuropathic pain through inhibiting p38 mitogen-activated protein kinase and nuclear factor-kappa B in a rat model of chronic constriction injury. Anesth Analg. 2014;118(5):1090\u201396. https:\/\/doi.org\/10.1213\/ANE.0000000000000174.","journal-title":"Anesth Analg"},{"issue":"16","key":"862_CR37","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1523\/JNEUROSCI.0003-06.2006","volume":"26","author":"BC Hains","year":"2006","unstructured":"Hains BC, Waxman SG. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J Neurosci. 2006;26(16):4308\u201317. https:\/\/doi.org\/10.1523\/JNEUROSCI.0003-06.2006.","journal-title":"J Neurosci"},{"issue":"1","key":"862_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000355071","volume":"22","author":"X-P Mei","year":"2014","unstructured":"Mei X-P, Sakuma Y, Xie C, Wu D, Ho I, Kotani J, et al. Depressing interleukin-1? Contributed to the synergistic effects of tramadol and minocycline on spinal nerve ligation-induced neuropathic pain. Neurosignals. 2014;22(1):30\u201342. https:\/\/doi.org\/10.1159\/000355071.","journal-title":"Neurosignals"},{"issue":"3","key":"862_CR39","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1523\/JNEUROSCI.23-03-01026.2003","volume":"23","author":"ED Milligan","year":"2003","unstructured":"Milligan ED, Twining C, Chacur M, Biedenkapp J, O\u2019Connor K, Poole S, et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci. 2003;23(3):1026. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-03-01026.2003.","journal-title":"J Neurosci"},{"key":"862_CR40","doi-asserted-by":"publisher","unstructured":"Mika J, Popiolek-Barczyk K, Rojewska E, Makuch W, Starowicz K, Przewlocka B. Delta-opioid receptor analgesia is independent of Microglial activation in a rat model of neuropathic pain. PLoS One. 2014;9(8):e104420. https:\/\/doi.org\/10.1371\/journal.pone.0104420.","DOI":"10.1371\/journal.pone.0104420"},{"issue":"11","key":"862_CR41","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1111\/j.1460-9568.2004.03754.x","volume":"20","author":"K Obata","year":"2004","unstructured":"Obata K, Yamanaka H, Dai Y, Mizushima T, Fukuoka T, Tokunaga A, et al. Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. Eur J Neurosci. 2004;20(11):2881\u201395. https:\/\/doi.org\/10.1111\/j.1460-9568.2004.03754.x.","journal-title":"Eur J Neurosci"},{"issue":"1\u20132","key":"862_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jneuroim.2014.09.020","volume":"277","author":"E Rojewska","year":"2014","unstructured":"Rojewska E, Popiolek-Barczyk K, Jurga AM, Makuch W, Przewlocka B, Mika J. Involvement of pro- and antinociceptive factors in minocycline analgesia in rat neuropathic pain model. J Neuroimmunol. 2014;277(1\u20132):57\u201366. https:\/\/doi.org\/10.1016\/j.jneuroim.2014.09.020.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"862_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/glia.10308","volume":"45","author":"M Tsuda","year":"2004","unstructured":"Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia. 2004;45(1):89\u201395. https:\/\/doi.org\/10.1002\/glia.10308.","journal-title":"Glia"},{"issue":"2","key":"862_CR44","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/01.ANES.0000270759.11086.E7","volume":"107","author":"YR Wen","year":"2007","unstructured":"Wen YR, Suter MR, Kawasaki Y, Huang J, Pertin M, Kohno T, et al. Nerve conduction blockade in the sciatic nerve prevents but does not reverse the activation of p38 mitogen-activated protein kinase in spinal microglia in the rat spared nerve injury model. Anesthesiology. 2007;107(2):312\u201321. https:\/\/doi.org\/10.1097\/01.ANES.0000270759.11086.E7.","journal-title":"Anesthesiology"},{"key":"862_CR45","doi-asserted-by":"publisher","first-page":"118149","DOI":"10.1016\/j.biopha.2025.118149","volume":"187","author":"K Pawlik","year":"2025","unstructured":"Pawlik K, Ciapa\u0142a K, Ciechanowska A, Makuch W, Mika J. Pharmacological modulation of neutrophils, in contrast to that of macrophages\/microglia, is sex independent and delays the development of morphine tolerance in a mouse model of neuropathic pain. Biomed Pharmacother. 2025;187:118149. https:\/\/doi.org\/10.1016\/j.biopha.2025.118149.","journal-title":"Biomed Pharmacother"},{"key":"862_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1744-8069-3-33","volume":"3","author":"R-R Ji","year":"2007","unstructured":"Ji R-R, Suter MR. p38 MAPK, Microglial signaling, and neuropathic pain. Mol Pain. 2007;3:33. https:\/\/doi.org\/10.1186\/1744-8069-3-33.","journal-title":"Mol Pain"},{"issue":"1\u20133","key":"862_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejphar.2013.01.072","volume":"716","author":"J Mika","year":"2013","unstructured":"Mika J, Zychowska M, Popiolek-Barczyk K, Rojewska E, Przewlocka B. Importance of glial activation in neuropathic pain. Eur J Pharmacol. 2013;716(1\u20133):106\u201319. https:\/\/doi.org\/10.1016\/j.ejphar.2013.01.072.","journal-title":"Eur J Pharmacol"},{"key":"862_CR48","unstructured":"Daiichi Sankyo launches \u201cTarlige\u00ae tablets\u201d for pain treatment in Japan - press releases - media - Daiichi Sankyo n.D. https:\/\/www.daiichisankyo.com\/media\/press_release\/detail\/index_3194.html. September 29, 2025."},{"key":"862_CR49","doi-asserted-by":"publisher","unstructured":"Mendell J, Levy-Cooperman N, Sellers E, Vince B, Kelsh D, Lee J, et al. Abuse potential of mirogabalin in recreational polydrug users. Ther Adv Drug Saf. 2019, 10;10. https:\/\/doi.org\/10.1177\/2042098619836032.","DOI":"10.1177\/2042098619836032"},{"issue":"5","key":"862_CR50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/PRP2.418","volume":"6","author":"K Brown","year":"2018","unstructured":"Brown K, Mendell J, Ohwada S, Hsu C, He L, Warren V, et al. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: results from phase 1 studies. Pharmacol Res & Perspec. 2018;6(5):6. https:\/\/doi.org\/10.1002\/PRP2.418.","journal-title":"Pharmacol Res & Perspec"},{"issue":"1","key":"862_CR51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/S00213-019-05356-3","volume":"237","author":"H Murasawa","year":"2020","unstructured":"Murasawa H, Kobayashi H, Saeki K, Kitano Y. Anxiolytic effects of the novel \u03b12\u03b4 ligand mirogabalin in a rat model of chronic constriction injury, an experimental model of neuropathic pain. Psychopharmacol (Berl). 2020;237(1):189\u201397. https:\/\/doi.org\/10.1007\/S00213-019-05356-3.","journal-title":"Psychopharmacol (Berl)"},{"key":"862_CR52","doi-asserted-by":"publisher","first-page":"113829","DOI":"10.1016\/J.BBR.2022.113829","volume":"425","author":"T Kochi","year":"2022","unstructured":"Kochi T, Nakamura Y, Ma S, Uemoto S, Hisaoka-Nakashima K, Irifune M, et al. Mirogabalin alleviates nociceptive hypersensitivity without causing sedation in a mouse model of post-traumatic trigeminal neuropathy. Behavioural Brain Res. 2022;425:113829. https:\/\/doi.org\/10.1016\/J.BBR.2022.113829.","journal-title":"Behavioural Brain Res"},{"key":"862_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/17448069211052167","volume":"17","author":"S Komatsu","year":"2021","unstructured":"Komatsu S, Nakamura S, Nonaka T, Yamada T, Yamamoto T. Analgesic characteristics of a newly developed \u03b12\u03b4 ligand, mirogabalin, on inflammatory pain. Mol Pain. 2021;17:17. https:\/\/doi.org\/10.1177\/17448069211052167.","journal-title":"Mol Pain"},{"issue":"6","key":"862_CR54","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/S00210-019-01628-Z","volume":"392","author":"K Saeki","year":"2019","unstructured":"Saeki K, Yasuda S-I, Kato M, Kano M, Domon Y, Arakawa N, et al. Analgesic effects of mirogabalin, a novel ligand for \u03b12\u03b4 subunit of voltage-gated calcium channels, in experimental animal models of fibromyalgia. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2019;392(6):723\u201328. https:\/\/doi.org\/10.1007\/S00210-019-01628-Z.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"862_CR55","doi-asserted-by":"publisher","first-page":"111647","DOI":"10.1016\/J.BIOPHA.2021.111647","volume":"139","author":"H Murasawa","year":"2021","unstructured":"Murasawa H, Pawlak A, Kobayashi H, Saeki K, Yasuda S-I, Kitano Y. Mirogabalin, a novel ligand for \u03b12\u03b4 subunit of voltage-gated calcium channels, improves cognitive impairments in repeated intramuscular acidic saline injection model rats, an experimental model of fibromyalgia. Biomed Pharmacother. 2021;139:111647. https:\/\/doi.org\/10.1016\/J.BIOPHA.2021.111647.","journal-title":"Biomed Pharmacother"},{"key":"862_CR56","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/10732748251353327","volume":"32","author":"Y Nakajima","year":"2025","unstructured":"Nakajima Y, Kuribayashi K, Tada A, Nagano A, Minami T, Kanehiro A, et al. Enhancing duloxetine with mirogabalin for treating taxane-induced peripheral neuropathy in advanced lung cancer. Cancer Control: J Moffitt Cancer Cent. 2025;32:32. https:\/\/doi.org\/10.1177\/10732748251353327.","journal-title":"Cancer Control: J Moffitt Cancer Cent"},{"issue":"2","key":"862_CR57","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1159\/000525059","volume":"15","author":"Y Saito","year":"2022","unstructured":"Saito Y, Takekuma Y, Oshino T, Sugawara M. Combination of mirogabalin and duloxetine attenuates peripheral neuropathy by Eribulin: a novel case report. Case Rep Oncol. 2022;15(2):606\u201310. https:\/\/doi.org\/10.1159\/000525059.","journal-title":"Case Rep Oncol"},{"key":"862_CR58","doi-asserted-by":"publisher","first-page":"1614587","DOI":"10.3389\/fphar.2025.1614587","volume":"16","author":"Z Guo","year":"2025","unstructured":"Guo Z, Xia Y, Zhang Z. Efficacy and safety of different medications compared for the treatment of postherpetic neuralgia: a network meta-analysis. Front Pharmacol. 2025;16:1614587. https:\/\/doi.org\/10.3389\/fphar.2025.1614587.","journal-title":"Front Pharmacol"},{"issue":"5","key":"862_CR59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/CNS.70460","volume":"31","author":"Y Wang","year":"2025","unstructured":"Wang Y, Wu C, Liu Y, Lou Y, Chen C, Chen Q, et al. Comparison of duloxetine supplemented with pregabalin and amitriptyline supplemented with pregabalin for the treatment of postherpetic neuralgia: a Double-blind, Randomized crossover trial. CNS Neurosci Ther. 2025;31(5):31. https:\/\/doi.org\/10.1111\/CNS.70460.","journal-title":"CNS Neurosci Ther"},{"key":"862_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.12688\/f1000research.130345.1","volume":"12","author":"K Krishnaprasad","year":"2023","unstructured":"Krishnaprasad K, Dutt S, Rattan P, Dadhania A, Gupta R, Joshi D, et al. Fixed dose combination of low dose pregabalin and duloxetine, or pregabalin monotherapy for neuropathic pain: a double-blind, randomized, parallel-group study. F1000Research. 2023;12:12. https:\/\/doi.org\/10.12688\/f1000research.130345.1.","journal-title":"F1000Research"},{"key":"862_CR61","doi-asserted-by":"publisher","unstructured":"Birkinshaw H, Friedrich CM, Cole P, Eccleston C, Serfaty M, Stewart G, et al. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database Systematic Rev. 2023;2023: CD014682. 5). https:\/\/doi.org\/10.1002\/14651858.CD014682.pub2.","DOI":"10.1002\/14651858.CD014682.pub2"},{"issue":"5","key":"862_CR62","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/00000542-199511000-00018","volume":"83","author":"JC Eisenach","year":"1995","unstructured":"Eisenach JC, Gebhart GF. Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Anesthesiology. 1995;83(5):1046\u201354. https:\/\/doi.org\/10.1097\/00000542-199511000-00018.","journal-title":"Anesthesiology"},{"issue":"5","key":"862_CR63","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/00000542-199511000-00017","volume":"83","author":"JC Eisenach","year":"1995","unstructured":"Eisenach JC, Gebhart GF. Intrathecal amitriptyline: antinociceptive interactions with intravenous morphine and intrathecal clonidine, neostigmine, and carbamylcholine in rats. Anesthesiology. 1995;83(5):1036\u201345. https:\/\/doi.org\/10.1097\/00000542-199511000-00017.","journal-title":"Anesthesiology"},{"issue":"2","key":"862_CR64","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0006-8993(95)00826-C","volume":"695","author":"D Ardid","year":"1995","unstructured":"Ardid D, Jourdan D, Mestre C, Villanueva L, Bars DL, Eschalier A. Involvement of bulbospinal pathways in the antinociceptive effect of clomipramine in the rat. Brain Res. 1995;695(2):253\u201356. https:\/\/doi.org\/10.1016\/0006-8993(95)00826-C.","journal-title":"Brain Res"},{"issue":"6","key":"862_CR65","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/SJ.BJP.0707253","volume":"151","author":"PK Gillman","year":"2007","unstructured":"Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737\u201348. https:\/\/doi.org\/10.1038\/SJ.BJP.0707253.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"862_CR66","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1097\/AJP.0000000000000343","volume":"32","author":"SM Hossain","year":"2016","unstructured":"Hossain SM, Hussain SM, Ekram ARMS. Duloxetine in painful diabetic neuropathy: a systematic review. Clin J Pain. 2016;32(11):1005\u201310. https:\/\/doi.org\/10.1097\/AJP.0000000000000343.","journal-title":"Clin J Pain"},{"key":"862_CR67","doi-asserted-by":"publisher","unstructured":"Migliorini F, Maffulli N, Eschweiler J, Baroncini A, Bell A, Colarossi G. Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis. J Orthop Surg Res. 2023, 18;18(1). https:\/\/doi.org\/10.1186\/S13018-023-03995-Z.","DOI":"10.1186\/S13018-023-03995-Z"},{"issue":"9","key":"862_CR68","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1002\/art.20485","volume":"50","author":"LM Arnold","year":"2004","unstructured":"Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheumatism. 2004;50(9):2974\u201384. https:\/\/doi.org\/10.1002\/art.20485.","journal-title":"Arthritis Rheumatism"},{"issue":"8","key":"862_CR69","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/S43465-025-01372-Y","volume":"59","author":"B Bhandari","year":"2025","unstructured":"Bhandari B, Bisht K, Purohit G, Gupta S, Singh GK, Goyal S, et al. Navigating the efficacy and safety landscape of duloxetine in osteoarthritis management: a meta-analysis of randomized controlled trials. JOIO. 2025;59(8):1123\u201336. https:\/\/doi.org\/10.1007\/S43465-025-01372-Y.","journal-title":"JOIO"},{"issue":"7","key":"862_CR70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/BRAINSCI15070757","volume":"15","author":"O Fraile-Martinez","year":"2025","unstructured":"Fraile-Martinez O, Garcia-Montero C, Alvarez-Mon MA, Ortega MA, Alvarez-Mon M, Quintero J. Delving into the perception, use, and context of duloxetine in clinical practice: an analysis based on the experience of healthcare professionals. Brain Sci. 2025;15(7):15. https:\/\/doi.org\/10.3390\/BRAINSCI15070757.","journal-title":"Brain Sci"},{"key":"862_CR71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/FPSYT.2020.554899","volume":"11","author":"D Rodrigues-Amorim","year":"2020","unstructured":"Rodrigues-Amorim D, Olivares JM, Spuch C, Rivera-Baltan\u00e1s T. A systematic review of efficacy, safety, and tolerability of duloxetine. Front. Psychiatry. 2020;11:11. https:\/\/doi.org\/10.3389\/FPSYT.2020.554899.","journal-title":"Front. Psychiatry"},{"issue":"1","key":"862_CR72","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/EJP.2044","volume":"27","author":"J Khan","year":"2023","unstructured":"Khan J, Wang Q, Korczeniewska OA, McNeil R, Ren Y, Benoliel R, et al. Response profile in a rat model of exercise-induced hypoalgesia is associated with duloxetine, pregabalin and diclofenac effect on constriction-induced neuropathy. Eur J Pain. 2023;27(1):129\u201347. https:\/\/doi.org\/10.1002\/EJP.2044.","journal-title":"Eur J Pain"},{"issue":"8","key":"862_CR73","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/J.PAIN.2012.04.023","volume":"153","author":"S Gr\u00e9goire","year":"2012","unstructured":"Gr\u00e9goire S, Michaud V, Chapuy E, Eschalier A, Ardid D. Study of emotional and cognitive impairments in mononeuropathic rats: effect of duloxetine and gabapentin. Pain. 2012;153(8):1657\u201363. https:\/\/doi.org\/10.1016\/J.PAIN.2012.04.023.","journal-title":"Pain"},{"issue":"11","key":"862_CR74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/IJMS18112483","volume":"18","author":"H Obata","year":"2017","unstructured":"Obata H. Analgesic mechanisms of antidepressants for neuropathic pain. IJMS. 2017;18(11):18. https:\/\/doi.org\/10.3390\/IJMS18112483.","journal-title":"IJMS"},{"key":"862_CR75","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/J.NEULET.2015.06.041","volume":"602","author":"H Hoshino","year":"2015","unstructured":"Hoshino H, Obata H, Saito S. Antihyperalgesic effect of duloxetine and amitriptyline in rats after peripheral nerve injury: influence of descending noradrenergic plasticity. Neurosci Lett. 2015;602:62\u201367. https:\/\/doi.org\/10.1016\/J.NEULET.2015.06.041.","journal-title":"Neurosci Lett"},{"issue":"1","key":"862_CR76","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1213\/ANE.0000000000002380","volume":"126","author":"S Ito","year":"2018","unstructured":"Ito S, Suto T, Saito S, Obata H. Repeated administration of duloxetine suppresses neuropathic pain by accumulating effects of noradrenaline in the spinal cord. Anesth Analg. 2018;126(1):298\u2013307. https:\/\/doi.org\/10.1213\/ANE.0000000000002380.","journal-title":"Anesth Analg"},{"key":"862_CR77","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/J.IBNEUR.2022.02.004","volume":"12","author":"D Kato","year":"2022","unstructured":"Kato D, Suto T, Obata H, Saito S. The efficacy of duloxetine depends on spinal cholinergic plasticity in neuropathic pain model rats. IBRO Neurosci Rep. 2022;12:188\u201396. https:\/\/doi.org\/10.1016\/J.IBNEUR.2022.02.004.","journal-title":"IBRO Neurosci Rep"},{"key":"862_CR78","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.neuroscience.2016.06.057","volume":"338","author":"M Kremer","year":"2016","unstructured":"Kremer M, Salvat E, Muller A, Yalcin I, Barrot M. Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights. Neuroscience. 2016;338:183\u2013206. https:\/\/doi.org\/10.1016\/j.neuroscience.2016.06.057.","journal-title":"Neuroscience"},{"issue":"1","key":"862_CR79","doi-asserted-by":"publisher","first-page":"74","DOI":"10.15557\/PiPK.2018.0010","volume":"18","author":"M Wojtera","year":"2018","unstructured":"Wojtera M, Sob\u00f3w T. Duloxetine: the pharmacological and clinical profile of a drug from the group of serotonin and noradrenaline reuptake inhibitors. Psychiatr. Psychol. Klin. 2018;18(1):74\u201380. https:\/\/doi.org\/10.15557\/PiPK.2018.0010.","journal-title":"PSYCHIATR. PSYCHOL. Klin"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00862-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00862-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00862-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:21:47Z","timestamp":1785856907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00862-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["862"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00862-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All applicable international, national, and institutional guidelines for the care and use of animals were followed. The number of animals was limited to the necessary minimum. The experiments were conducted in accordance with the recommendations and standards of the International Association for the Study of Pain and the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Ethical Committee of the Maj Institute of Pharmacology of the Polish Academy of Sciences (permission numbers: LKE: 192\/2022; 142\/2025).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}